|
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
RECRUITINGPhase 3Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2026-08-26
Est. completion2029-08
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations80 sites
View on ClinicalTrials.gov →
NCT07794579
Summary
This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Have an increased waist-to-height ratio of ≥0.5 * Have at least one pre-obesity-related complication (prediabetes, prehypertension, predyslipidemia) * Have at least one unsuccessful attempt to reduce body weight based on diet and exercise * Have a BMI greater than or equal to 25 to less than or equal to 29.9 kg/m2 or equivalent-/region-specific overweight thresholds Exclusion Criteria: * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Do not have a stable body weight within 90 days before screening * Have a documented obesity diagnosis or self-reported history of BMI ≥30 kg/m² (or an equivalent region-specific threshold) * Have taken medications for weight loss, including over-the counter medications or alternative therapies, within 180 days prior to screening * Have a prior or planned surgical treatment or procedure for obesity * Have hypertension or history of hypertension * Have dyslipidemia or history of dyslipidemia
Conditions5
DiabetesObesity, AbdominalOverweightPrediabetic StatePrehypertension
Interventions1
Locations80 sites
Find trials near these locations
Diabetes trials in MesaDiabetes trials in PhoenixDiabetes trials in TucsonDiabetes trials in Long BeachDiabetes trials in Los AngelesDiabetes trials in SacramentoDiabetes trials in MiamiDiabetes trials in OrlandoDiabetes trials in AtlantaDiabetes trials in ChicagoDiabetes trials in LouisvilleDiabetes trials in BostonAll trials in AlabamaAll trials in ArizonaAll trials in CaliforniaAll trials in ConnecticutAll trials in FloridaAll trials in GeorgiaAll trials in IdahoAll trials in IllinoisAll trials in IowaAll trials in KansasAll trials in KentuckyAll trials in LouisianaAll trials in MarylandAll trials in MassachusettsAll trials in MichiganAll trials in MinnesotaAll trials in MissouriAll trials in NevadaAll trials in New JerseyAll trials in New YorkAll trials in North CarolinaAll trials in North DakotaAll trials in OhioAll trials in OklahomaAll trials in OregonAll trials in PennsylvaniaAll trials in South CarolinaAll trials in TennesseeAll trials in TexasAll trials in VirginiaAll trials in West Virginia
Related trials
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting — Eli Lilly and Company
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) — Eli Lilly and Company
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes — Eli Lilly and Company
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 3
SponsorEli Lilly and Company
Started2026-08-26
Est. completion2029-08
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations80 sites
View on ClinicalTrials.gov →
NCT07794579